| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3651 |
| Trial ID | NCT06116110 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Zamtocabtagene Autoleucel|MB-CART2019.1 |
| Recruitment status | Not Recruiting |
| Title | A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study |
| Year | 2024 |
| Country | United States |
| Company sponsor | Miltenyi Biomedicine GmbH |
| Other ID(s) | M-2023-401 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||